依洛尤单抗在代谢综合征合并ASCVD患者中的疗效与安全性:FOURIER试验二次分析
IMPORTANCE: The PCSK9 inhibitor evolocumab reduced low-density lipoprotein cholesterol and cardiovascular events in the FOURIER randomized clinical trial. Patients with metabolic syndrome (MetS) are at increased cardiovascular risk.…
要点
- 代谢综合征患者即使接受他汀治疗,主要心血管终点风险仍显著升高(校正HR 1.31)。
- 依洛尤单抗在合并代谢综合征患者中主要终点HR 0.83(95%CI 0.76-0.91),与无代谢综合征者疗效一致。
- 依洛尤单抗不增加新发糖尿病或血糖控制恶化等安全性事件。
核心结论
- 合并代谢综合征的动脉粥样硬化性心血管疾病患者在接受他汀治疗后仍存在显著残余心血管风险。
- 依洛尤单抗可显著降低代谢综合征患者的LDL-C和心血管风险,且不增加新发糖尿病或血糖控制恶化等安全性事件。
- 在动脉粥样硬化性心血管疾病合并代谢综合征患者中,在他汀基础上加用依洛尤单抗是安全有效的。
研究设计与样本
- 按NCEP ATP III代谢综合征标准分层,并按基线糖尿病进一步亚组分析,采用意向性治疗分析。
主要发现
- 代谢综合征患者主要终点校正HR 1.31(95%CI 1.18-1.46,P<.001),关键次要终点校正HR 1.38(95%CI 1.20-1.57,P<.001)。
- 依洛尤单抗在合并代谢综合征患者中LDL-C中位数从92 mg/dL降至30 mg/dL(P<.001),无代谢综合征者从92 mg/dL降至29 mg/dL(P<.001)。
关键数值与推荐
- 代谢综合征定义采用NCEP ATP III标准。
- 主要终点为心血管死亡、心肌梗死、卒中、不稳定心绞痛住院或冠状动脉血运重建。
- 关键次要终点为心血管死亡、心肌梗死或卒中。
临床怎么用
- 对接受他汀治疗的动脉粥样硬化性心血管疾病合并代谢综合征患者,可考虑加用依洛尤单抗以降低残余心血管风险。
- 依洛尤单抗在代谢综合征患者中不增加新发糖尿病或血糖控制恶化风险,安全性可接受。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The PCSK9 inhibitor evolocumab reduced low-density lipoprotein cholesterol and cardiovascular events in the FOURIER randomized clinical trial. Patients with metabolic syndrome (MetS) are at increased cardiovascular risk. OBJECTIVE: To investigate outcomes with evolocumab in patients with and without MetS. DESIGN, SETTING, AND PARTICIPANTS: The FOURIER trial randomized patients worldwide with stable atherosclerotic cardiovascular disease receiving statin to evolocumab vs placebo with follow-up for a median of 2.2 years. Data were collected February 2013 to November 2016. For this prespecified analysis, patients with the requisite data were stratified based on the National Cholesterol Education Program Adult Treatment Panel III MetS criteria; in secondary analyses, patients were further substratified by diabetes at baseline. Analysis was intention to treat. Analysis began March 2018 and ended April 2020. INTERVENTIONS: Patients were randomized to evolocumab or placebo. MAIN OUTCOMES AND MEASURES: The primary end point was cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization. The key secondary end point was cardiovascular death, myocardial infarction, or stroke. RESULTS: Of 27 342 patients (mean [SD] age, 63 [9] years; 20 623 men [75.4%]) included in this analysis, 16 361 (59.8%) with baseline MetS were, when compared with patients without MetS, at higher risk of cardiovascular events (adjusted hazard ratio [95% CI], 1.31 [1.18-1.46]; P < .001 for the primary and 1.38 [1.20-1.57]; P < .001 for the key secondary end point). Evolocumab reduced low-density lipoprotein cholesterol similarly in patients with MetS (median [interquartile range], 92 [79-109] mg/dL vs 30 [19-48] mg/dL; P < .001) and without MetS (median [interquartile range], 92 [81-108] mg/dL vs 29 [18-44] mg/dl; P < .001). For the primary end point, the hazard ratios (95% CI) with evolocumab vs placebo were 0.83 (0.76-0.91) and 0.89 (0.79-1.01) in patients with and without MetS (P for interaction = .39). For the key secondary end point, the corresponding hazard ratios (95% CIs) were 0.76 (0.68-0.86) and 0.86 (0.74-1.01) (P for interaction = .23), respectively. Evolocumab did not increase the risk of new-onset diabetes or other major safety outcomes including worsening glycemic control, compared with placebo in patients with MetS. CONCLUSIONS AND RELEVANCE: Patients with atherosclerotic cardiovascular disease and MetS have substantial residual risk of cardiovascular events despite statin therapy. Evolocumab significantly reduced low-density lipoprotein cholesterol and cardiovascular risk in patients with MetS without increasing new-onset diabetes, worsening glycemic control, or other major safety events. These data suggest the addition of evolocumab to statin therapy in patients with atherosclerotic cardiovascular disease and MetS is safe and efficacious to reduce residual cardiovascular risk. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01764633.
引用
- Deedwania P, Murphy SA, Scheen A, et al. Efficacy and Safety of PCSK9 Inhibition With Evolocumab in Reducing Cardiovascular Events in Patients With Metabolic Syndrome Receiving Statin Therapy: Secondary Analysis From the FOURIER Randomized Clinical Trial. JAMA Cardiol. 2021. PMID: 32785614. doi:10.1001/jamacardio.2020.3151
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。